WHO ICTRP trial
DAREON-8: A study to test how well different doses of BI 764532 in addition to…
JPRN-jRCT2031230615 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2031230615 |
|---|---|
| Public title | DAREON-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small cell lung cancer |
| Scientific title | DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with standard of care (platinum, etoposide, and anti-PDL1) in patients with extensive-stage small cell lung carcinoma |
| Primary sponsor | Tahara Eriko |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 1 |
| Countries | United State;Japan;Spain;Japan;Poland;Japan;Switzerland;Japan;Germany;Japan;France;Japan;Belgium;Japan |
| Conditions | Histologically or cytologically confirmed ES-SCLC |
| Interventions | Part A - Administer BI 764532 in combination with SoC with platinum, etoposide, and anti-PD-L1 antibody. Part B - Administer BI 764532 in combination with different standard treatment regimens (chemotherapy and anti-PD-L1 antibodies). |
| Registration date | Jan 2, 2024 |
| Target size | 60 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: